Literature DB >> 29358317

Clinical Course of Multiple Sclerosis.

Sylvia Klineova1, Fred D Lublin1.   

Abstract

The 1996 originally established multiple sclerosis (MS) subtypes, based solely on clinical impression and consensus, were revised in 2013 to review potential imaging and biological correlates and to reflect recently identified clinical aspects of MS. As a result, potential new disease phenotypes, radiologically isolated syndrome, and clinically isolated syndrome were considered along with the addition of two new descriptor subtypes: activity and progression applied to relapsing remitting and progressive MS phenotypes. In this way, the description of an individual patient's disease course is refined and provides temporal information about the ongoing disease process. There is still a lack of imaging and biological markers that would distinguish MS phenotypes and prognosticate the disease course on an individual patient's level, creating a pressing need for large collaborative research efforts in this field.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29358317      PMCID: PMC6120692          DOI: 10.1101/cshperspect.a028928

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  40 in total

Review 1.  Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis.

Authors:  David C Mohr; Stacey L Hart; Laura Julian; Darcy Cox; Daniel Pelletier
Journal:  BMJ       Date:  2004-03-19

Review 2.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 3.  Th17 cells in central nervous system autoimmunity.

Authors:  Christopher Sie; Thomas Korn; Meike Mitsdoerffer
Journal:  Exp Neurol       Date:  2014-03-27       Impact factor: 5.330

Review 4.  The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology.

Authors:  Massimo Filippi; Maria A Rocca
Journal:  Acta Neurol Belg       Date:  2011-06       Impact factor: 2.396

5.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

Review 6.  B cells and antibodies in CNS demyelinating disease.

Authors:  A H Cross; J L Trotter; J Lyons
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

7.  The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

Authors:  M Kremenchutzky; G P A Rice; J Baskerville; D M Wingerchuk; G C Ebers
Journal:  Brain       Date:  2006-01-09       Impact factor: 13.501

8.  Effect of relapses on development of residual deficit in multiple sclerosis.

Authors:  Fred D Lublin; Monika Baier; Gary Cutter
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

9.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

Authors:  Peter A Brex; Olga Ciccarelli; Jonathon I O'Riordan; Michael Sailer; Alan J Thompson; David H Miller
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

10.  Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Authors:  Darin T Okuda; Aksel Siva; Orhun Kantarci; Matilde Inglese; Ilana Katz; Melih Tutuncu; B Mark Keegan; Stacy Donlon; Le H Hua; Angela Vidal-Jordana; Xavier Montalban; Alex Rovira; Mar Tintoré; Maria Pia Amato; Bruno Brochet; Jérôme de Seze; David Brassat; Patrick Vermersch; Nicola De Stefano; Maria Pia Sormani; Daniel Pelletier; Christine Lebrun
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more
  37 in total

Review 1.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

Review 2.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 3.  Seasonal and monthly variation in multiple sclerosis relapses: a systematic review and meta-analysis.

Authors:  Fardin Nabizadeh; Parya Valizadeh; Maryam Yazdani Tabrizi; Kimia Moayyed; Niousha Ghomashi; Omid Mirmosayyeb
Journal:  Acta Neurol Belg       Date:  2022-09-28       Impact factor: 2.471

4.  Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heralding Prodrome.

Authors:  Qiling Ji; Huiqing Dong; Hangil Lee; Zheng Liu; Yanna Tong; Kenneth Elkin; Yazeed Haddad; Xiaokun Geng; Yuchuan Ding
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

Review 5.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

Review 6.  Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?

Authors:  Min Joung Kim; Jung Hee Kang; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos
Journal:  Cells       Date:  2018-12-20       Impact factor: 6.600

7.  Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.

Authors:  Yumeng Song; Yongfeng Lao; Fuxiang Liang; Jing Li; Bibo Jia; Zixuan Wang; Xu Hui; Zhenxing Lu; Biao Zhou; Wei Luo; Bing Song
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y12 Pathway in Multiple Sclerosis.

Authors:  Angela Dziedzic; Elzbieta Miller; Joanna Saluk-Bijak; Marta Niwald; Michal Bijak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 9.  The Role of B Cells in Primary Progressive Multiple Sclerosis.

Authors:  Jameson P Holloman; Robert C Axtell; Nancy L Monson; Gregory F Wu
Journal:  Front Neurol       Date:  2021-06-07       Impact factor: 4.086

Review 10.  The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis.

Authors:  Kelly L Monaghan; Edwin C K Wan
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.